Relugolix with estradiol and norethisterone acetate - Uterine fibroids

You are here : Home > Formulary Search > Relugolix with estradiol and norethisterone acetate - Uterine fibroids

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue

Formulations :

Tablets

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

NICE

Restrictions / Comments :

Documentation

Evidence Review

Relugolix - estradiol - norethisterone - NICE briefing paper - January 2023.pdf

Webpage

NICE TA832 - Relugolix - estradiol - norethisterone for symptom control of uterine fibroids - October 22

PAD Profile

ChemicalSubstance :

Relugolix with estradiol and norethisterone acetate

Indication :

Uterine fibroids

Group Name :

Keywords :

Heavy Menstral Bleeding

Brand Names Include :

Ryeqo

Important Information :

Specialist team initiation and at least 3 months of treatment prior to any request for primary care prescribing.

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Relugolix with estradiol and norethisterone acetate is used to treat.

Endometriosis

Other Drugs

Below are listed other drugs that are used to treat Uterine fibroids.

Committee Recommendations (1)

04 Jan 23 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System approves the use of relugolix-estradiol-norethisterone as recommended by NICE TA832 as an option for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.

Relugolix-estradiol-norethisterone will be given a BLUE (no information sheet) traffic light status for this indication with specialist initiation and continued prescribing for at least 3 months prior to transfer of care to primary care prescribers.

A DXA scan is recommended after the first 52 weeks of treatment to verify that the patient does not have an unwanted degree of BMD loss, that exceeds the benefit of treatment. This DXA scan will be organised & performed by the specialist team responsible for the ongoing care of the patient.